Posted by Michael Wonder on 11 Sep 2017
NICE: We're the institute of 'yes'
11 September 2017 - But Meindert Boysen says affordability conversations with pharma need to happen earlier.
NICE is on pharma's side and provides England and Wales with secure access to new medicines, the Institute's programme director of technology appraisals has said.
But Meindert Boysen told a London meeting conversations between the cost-effectiveness watchdog and the industry about value need to be conducted in a more open manner.
“We're producing 80% positive recommendations, this is secure access. Many people think we're the institute of 'no', but actually we're the institute of 'yes'," he said.
